‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says Expert

Video

Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.

Questions concerning disease recurrence among patients with renal cell carcinoma—a type of kidney cancer—need to be answered with future research, according to Axel Bex, MD, PhD, a urologic surgeon at the Specialist Centre For Kidney Cancer, Royal Free London NHS Foundation Trust, and a professor at University College London, Division of Surgery and Interventional Science.

During the 2022 Society for Urologic Oncology (SUO) Annual Meeting, CancerNetwork® spoke with Bex about his presentation on new developments in adjuvant therapy for renal cell carcinoma.

Bex also said that the use of gene-expression profiles as predictive biomarkers of treatment response is another development in the field that is being explored in the BIONIKK trial (NCT02960906), which is evaluating nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic kidney cancer. Reducing the rate of overtreatment for metastatic kidney cancer is another important challenge, according to Bex.

Transcript:

First of all, we know from the metastatic setting that there are certain molecular subtypes that seem to predict that these patients respond better to immunotherapy, but they haven't made it into general practice yet as biomarkers. But as we heard here at SUO, there are some trials being planned.

We also have the BIONIKK trial in Europe, for example, that would look at certain gene expression profiles, and select patients who are much more likely to respond. Now, what we need to avoid in the future is there's a 40% over-treatment rate. That's something we already learned from [tumor growth inhibition] trials. It is absolutely important that we improve our prediction of recurrences. Patients want to know: do [my diseases] recur? And if so, is there something that helps me? And if there's something that helps me, is it likely that I will respond to it? These 2 questions need to be answered, and I think we have the tools.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content